ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 17 for:    Recruiting, Not yet recruiting, Active, not recruiting Studies | Amyotrophic Lateral Sclerosis | Canada
Previous Study | Return to List | Next Study

Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03321487
Recruitment Status : Recruiting
First Posted : October 25, 2017
Last Update Posted : April 30, 2018
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent in patients with Amyotrophic Lateral Sclerosis (ALS).

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Device: Blood-Brain Barrier opening with MRgFUS Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Feasibility of Primary Motor Cortex Blood-Brain Barrier Opening Using Transcranial MR-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agent in Patients With Amyotrophic Lateral Sclerosis
Actual Study Start Date : April 13, 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019


Arm Intervention/treatment
Experimental: Stage I Cohort
Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
Device: Blood-Brain Barrier opening with MRgFUS
ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
Other Names:
  • Focused Ultrasound (FUS)
  • Blood-Brain Barrier Disruption (BBBD)
  • ExAblate MRgFUS

Experimental: Stage II Cohort
Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
Device: Blood-Brain Barrier opening with MRgFUS
ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
Other Names:
  • Focused Ultrasound (FUS)
  • Blood-Brain Barrier Disruption (BBBD)
  • ExAblate MRgFUS




Primary Outcome Measures :
  1. Safety - Device and Procedure related adverse events [ Time Frame: At the time of the ExAblate MRgFUS procedure ]
    The number and severity of device and BBB opening procedure related adverse events will be evaluated.


Secondary Outcome Measures :
  1. Degree of contrast enhancement seen on post-procedure MRI [ Time Frame: At the time of the ExAblate MRgFUS procedure and 24 hours post-procedure ]
    The extent and reversibility of BBB opening will be determined by the degree of contrast enhancement seen on post-procedure MRI with gadolinium-based contrast agent.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria (Brooks et al. 2000).
  2. Right-hand dominant male or female aged 18 years or older.
  3. Capable of providing informed consent and complying with study procedures, including tolerability in the supine position and MRI examination without significant claustrophobia.
  4. If taking riluzole, on a stable dose for at least 30 days prior to Screening Visit.
  5. Slow Vital Capacity equal to or more than 50% predicted value for gender, height and age in the 30 days prior to the Screening Visit and able to lie supine without BiPAP.
  6. Severe left arm weakness and functional impairment, defined as Medical Research Council muscle strength score equals 3 or less in the index finger abduction and thumb abduction on the left side; OR severe left leg weakness and functional impairment, defined as Medical Research Council muscle strength score equals 3 or less at the hip flexors and ankle dorsiflexors on the left side.
  7. Able to communicate during the ExAblate® MRI-guided FUS procedure.

Exclusion Criteria:

  1. Unable to complete high-density CT and MRI studies of the head at the Screening Visit or any other MRI contraindication, such as:

    • Large body habitus and not fitting comfortably into the scanner
    • Difficulty lying supine and still for up to 3 hours in the MRI unit or significant claustrophobia
  2. MRI findings:

    • Active infection/inflammation
    • Acute or chronic brain hemorrhages, specifically lobar or subcortical microbleeds, siderosis or macrohemorrhages
    • Tumor/space occupying lesion
    • Meningeal enhancement
  3. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.
  4. Clips or other metallic implanted objects in the skull or the brain, except shunts.
  5. Significant cardiac disease or unstable hemodynamic status including:

    • Documented myocardial infarction within six months of enrollment
    • Unstable angina on medication
    • Unstable or worsening congestive heart failure
    • Left ventricular ejection fraction below the lower limit of normal
    • History of a hemodynamically unstable cardiac arrhythmia
    • Cardiac or phrenic pacemaker
    • Known right-to-left, bidirectional, or transient right-to-left cardiac shunt
    • Patients with relative contraindications to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation,
    • QT prolongation observed on screening ECG (QTc > 450 for men and >470 for women)
  6. Uncontrolled hypertension (systolic > 150 or diastolic BP > 100 on medication).
  7. On medications that increase the bleeding risk, specifically: a) aspirin or another antiplatelet medication (clopidogrel, prasugrel, ticlopidine, abciximab) for the last 7 days prior to treatment; b) oral, subcutaneous or intravenous anticoagulant medications, such as oral vitamin K inhibitors for the last 7 days, non-vitamin K inhibitor oral anticoagulant (dabigatran, apixaban, rivaroxaban) for the last 72 hours, and intravenous or subcutaneous heparin-derived compounds for the last 48 hours.
  8. History of a bleeding disorder, coagulopathy or a history of spontaneous hemorrhage.
  9. Known frontotemporal dementia.
  10. Abnormal coagulation profile, specifically: platelet <100,000/μl, Prothrombin Time >14 seconds, activated partial thromboplastin time (aPTT) >36 seconds, and INR > 1.3.
  11. Known cerebral or systemic vasculopathy, specifically cerebral amyloid angiopathy or systemic or central nervous system vasculitis.
  12. Known auto-immune condition with or without neurological manifestations (e.g., multiple sclerosis (MS), systemic lupus erythematous (SLE), Rheumatoid arthritis).
  13. Current or planned use of oral, intramuscular or intravenous steroid drugs (such as prednisone, prednisolone, dexamethasone, triamcinolone, methylprednisolone, oxandrolone, and others) or immunosuppressant drugs (azathioprine, mycophenolate, tacrolimus, sirolimus, cyclophosphamide, and others) for more than 7 days.
  14. Known sensitivity/allergy to gadolinium (an alternative product may be used), DEFINITY® contrast or any of its components.
  15. Untreated, uncontrolled sleep apnea.
  16. Impaired renal function with cystatin C-based estimated glomerular filtration rate <30 mL/min/1.73m2 and acute renal injury.
  17. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device.
  18. Known respiratory diseases, specifically: chronic pulmonary disorders e.g., severe/uncontrolled COPD, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area, asthma or hay fever.
  19. Patients with a history of drug allergies or multiple allergies where the benefit/risk of administering DEFINITY® is considered unfavorable by the study physicians in relation to the product monograph for DEFINITY®.
  20. Unqualified fit for the anesthesia by an anesthesiologist assessment, ASA I-III.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03321487


Locations
Canada, Ontario
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Alison Bethune    416-480-6100 ext 3773    focusedultrasound@sunnybrook.ca   
Principal Investigator: Lorne Zinman, MD         
Sponsors and Collaborators
InSightec
Investigators
Principal Investigator: Lorne Zinman, MD Medical Director, ALS/Neuromuscular Clinic, Sunnybrook Health Sciences Centre

Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT03321487     History of Changes
Other Study ID Numbers: ALSFUS001
First Posted: October 25, 2017    Key Record Dates
Last Update Posted: April 30, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by InSightec:
Blood-Brain Barrier disruption
Blood-Brain Barrier opening
magnetic resonance-guided focused ultrasound

Additional relevant MeSH terms:
Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases